BIVI 250117 2.50C (BIVI250117C2500) Stock Options, News & Quotes

US OptionsDetailed Quotes

BIVI250117C2500

Watchlist

0.15
0.000.00%

15min DelayClose Aug 5 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

BioVie Files to Sell 7.71M Shares of Common Stock for Holders
TipRanksNov 21 17:35 ET
BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference
GlobeNewswireNov 20 08:00 ET
BioVie | 10-Q: Q1 2025 Earnings Report
SECNov 13 16:52 ET · Announcements
Express News | BioVie Inc - Pd-202 Trial Expected to Start Early 2025, Results by Late 2025
ReutersNov 4 08:00 ET
BioVie's Upcoming Parkinson's Disease Clinical Trial Is Fully Funded
Yahoo FinanceNov 4 08:00 ET
Express News | Biovie’s Upcoming Parkinson’s Disease Clinical Trial Is Fully Funded
ReutersNov 4 08:00 ET

Comments

Jaguar8

Nov 20 07:07

NEWS

$BioVie (BIVI.US)$
BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference
BioVie (NASDAQ: BIVI) announced the acceptance of an abstract detailing their planned Phase 2 trial of bezisterim for Long COVID treatment at the Demystifying Long COVID International Conference in Barcelona. The study, fully funded by the U.S. Department of Defense, will be a double-blind, randomized, placebo-controlled tri...